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CLINICAL ARTICLES
Bacteremia Caused by Staphylococci with Inducible Vancomycin
Heteroresistance
Samson S. Y. Wong, P. L. Ho, Patrick C. Y. Woo,
and K. Y. Yuen
From the Division of Infectious Diseases, Department of Microbiology,
The University of Hong Kong, Queen Mary Hospital, Hong Kong
The clinical significance of bacteremia due to vancomycin-heteroresistant staphylococci and a
rapid laboratory screening method were examined; 203 strains of staphylococci isolated from
patients with clinically significant bacteremia were screened by the disk-agar method with use of
vancomycin-salt agar to demonstrate satellitism around an aztreonam disk as well as by conven-
tional population screening. Eighteen isolates (three Staphylococcus aureus and 15 coagulase-
negative staphylococci) were shown to be heteroresistant to vancomycin. A case-control clinical
study showed that the interval between admission and bacteremia, admission to the intensive care
unit, prior use of vancomycin and/or b-lactams, and isolation of methicillin-resistant staphylococci
were significantly more common among patients with bacteremia due to staphylococci with hetero-
resistance to vancomycin; these patients had an overall mortality of 44.4%. The use of vancomycin
and admission to the intensive care unit were independently significant risk factors on multivariate
analysis. Vancomycin heteroresistance is inducible by salt and b-lactams. Indiscriminate sequential
use of b-lactams and glycopeptides may facilitate the emergence of glycopeptide resistance.
Glycopeptides have long been the last resort in the treatment
of serious infections due to multiresistant gram-positive organ-
isms. The alarming emergence of Staphylococcus aureus with
intermediate resistance to vancomycin [1–3] and S. aureus with
heteroresistance to vancomycin [4] was recently reported, and
therapeutic failures with glycopeptides have been observed in
treatment of infections due to S. aureus with intermediate
vancomycin resistance [1, 3]. However, routine laboratory de-
tection of S. aureus with intermediate resistance and with
heteroresistance to vancomycin is difficult and not yet stan-
dardized. The terminology for staphylococci with reduced sus-
ceptibility to glycopeptides still needs refinement, as different
break points are used by different investigators to define resis-
tance.
See editorial response by Moellering on pages 768–70.
The exact clinical significance of vancomycin-heteroresistant
staphylococci is still unknown. Even less is known about this
phenomenon among coagulase-negative staphylococci (CNS),
which have emerged as important nosocomial pathogens in recent
years. Previous in vitro study of Staphylococcus haemolyticus [5]
has demonstrated that vancomycin resistance is detectable only
among imipenem-resistant strains and that the phenotypic resis-
tance is inducible by imipenem. The addition of 2% NaCl to
Mueller-Hinton culture broth was necessary for the growth of
resistant clones in the presence of high concentrations of vanco-
mycin. We made use of such growth characteristics in the design
of a disk-agar screening method for the rapid screening of salt-
and aztreonam-inducible vancomycin heteroresistance among
staphylococcal isolates obtained from blood. The clinical char-
acteristics and outcome of these patients are reported in a
case-control study.
Materials and Methods
Strains of staphylococci were isolated from blood between 1
July 1997 to 30 June 1998 at the Department of Microbiology,
Queen Mary Hospital, a 1,400-bed tertiary care and university
teaching hospital. All S. aureus isolated during this period were
included in the study. CNS were selected only if the same
strain was isolated on culture of blood from two different sites
from the same febrile patient or if the isolate from blood was
identical to that obtained by culture from central venous cath-
eters and determined to be positive by the roll plate method
with .15 cfu [6]. There were no duplicate isolates from the
same patient. Staphylococci were identified by conventional
biochemical tests [7], including the Staphaurex latex aggluti-
nation kit (Murex Biotech, Dartford, UK) and tube coagulase
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test; the identity was further confirmed by the Vitek gram-
positive card (bioMe´rieux Vitek, Hazelwood, MO). Routine
antibiotic sensitivity testing was done by the disk diffusion
method (BBL Sensi-Disc; Becton Dickinson, Cockeysville,
MD) according to guidelines of the National Committee for
Clinical Laboratory Standards (NCCLS) [8, 9]. A strain of
vancomycin-resistant S. haemolyticus and S. aureus ATCC
29213 were used as controls throughout the study.
Screening for potential vancomycin resistance by population
screening. S. aureus strains were screened for potential van-
comycin resistance as previously described [4]. Ten microliters
of a bacterial suspension made from an overnight agar culture
adjusted to McFarland standard 0.5 was spread on brain-heart
infusion agar (Oxoid, Basingstoke, UK) with 4 mg/mL vanco-
mycin and incubated at 37°C for 48 h. The presence of growth
(initial positive, table 1) as well as the number of colonies were
noted at 48 h. The vancomycin MICs for these subclones were
first determined by the Etest (AB BIODISK, Solna, Sweden)
and then confirmed by the broth macrodilution method if the
vancomycin MIC was Ä4 mg/mL by Etest.
Screening for potential vancomycin resistance by the disk-
agar method. Vancomycin-salt agar was prepared by incor-
porating 4 mg/mL vancomycin and 4% NaCl into Mueller-
Hinton agar (Oxoid). Agar was poured into 85-mm Petri
dishes, with a 4-mm depth of agar. An overnight blood agar
plate culture of the isolates was used to make a bacterial
suspension of McFarland 1 turbidity in 0.9% saline. The agar
was evenly inoculated by a sterile cotton swab dipped into the
suspension and pressed firmly on the inside of the tube to
remove excess inoculum from the swab. A 30-mg aztreonam
disk (BBL Sensi-Disc; Becton Dickinson) was placed on the
agar surface 5 minutes afterwards. The plates were incubated at
37°C for 48 hours. The largest single colony on the
vancomycin-salt agar demonstrating satellitism around the az-
treonam disk was picked out for determination of vancomycin
MIC by the Etest, followed by confirmation with the macro-
broth dilution method if the vancomycin MIC by the Etest was
Ä4 mg/mL.
Confirmation of identity and MIC determination. Colonies
that grew on vancomycin-containing agar were retested bio-
chemically to confirm their identity. Final determinations of
vancomycin MICs were done by the broth macrodilution
method [10] and Etest with and without the addition of NaCl to
the medium (2% and 4% NaCl to the Mueller-Hinton broth and
agar, respectively). For the broth macrodilution method, the
inoculum was 5 3 105 cfu/mL (range, 3–7 3 105 cfu/mL) and
was confirmed by back titration and plating on blood agar
plates. The serial concentrations of vancomycin in the Mueller-
Hinton broth were confirmed by use of the TDX Analyzer
(Abbott Laboratories, North Chicago, IL) prior to the test.
Strains that were identified as S. haemolyticus were excluded
from the study if they showed homogenous resistance to van-
comycin by disk diffusion testing.
Case-control study. Patients with bacteremia due to staph-
ylococci with heteroresistance to vancomycin were defined as
cases. Age- and sex-matched controls were taken from patients
with staphylococcal bacteremia in the same period but whose
isolates did not demonstrate vancomycin heteroresistance.
Ages of control patients were 63 years of the respective
case-patient for adults or 61 month for infants and neonates.
Demographic and clinical information for the cases and con-
trols were compared to identify characteristics associated with
bacteremia due to staphylococci with heteroresistance to van-
comycin. The x2 test was used for statistical analysis, and P ,
.05 was considered statistically significant. Variables that were
statistically significant were further tested by multivariate lo-
gistic analysis by use of the backward elimination method.
Table 1. Comparison of results of testing for vancomycin resistance by using population screening and
disk-agar methods.
Classification of isolates No. tested
No. initially positive*
by population
screening
No. initially positive*
by disk-agar method
No. with confirmed
heteroresistance to
vancomycin†
Methicillin-susceptible
Staphylococcus aureus 112 3 0 0
Methicillin-resistant
S. aureus 52 21 5 3
Methicillin-susceptible
coagulase-negative
staphylococci 8 0 0 0
Methicillin-resistant
coagulase-negative
staphylococci 31 28 21 15
Total 203 52 26 18
* Strains that are initially positive had subpopulations that grew on the screening plates.
† Strains are referred to as having confirmed heteroresistance to vancomycin if the vancomycin MIC of these
subpopulations was Ä8 mg/mL.
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Definitions. Methicillin resistance was defined as an ox-
acillin MIC of Ä4 mg/mL as tested by use of the NCCLS
method [8]. An isolate was defined as having intermediate
vancomycin resistance if the vancomycin MIC was .4 but
,32 mg/mL, whereas vancomycin resistance was defined as an
MIC of Ä32 mg/mL [8]. Heteroresistance to vancomycin was
defined as occurring if a strain produced a subclone(s) at a
frequency of Ä1026 colonies with vancomycin MIC of Ä8
mg/mL on selection by the population screening, with the
stability of the strain persisting beyond 9 days in an antibiotic-
free medium [4]. An episode of bacteremia was considered
nosocomial in origin if the time between admission and the
date of positive blood culture was .2 days [11].
Results
Two hundred three strains of staphylococci from blood were
retrieved for screening, comprising 112 methicillin-sensitive
S. aureus, 52 methicillin-resistant S. aureus, 8 methicillin-
sensitive CNS, and 31 methicillin-resistant CNS (table 1).
Eighteen strains (table 2) demonstrated heteroresistance to
vancomycin after screening by the disk-agar method, including
3 strains of methicillin-resistant S. aureus (5.8% prevalence)
and 15 strains of methicillin-resistant CNS (48.4% prevalence).
Six of these 15 CNS were identified as Staphylococcus epider-
midis and three were Staphylococcus capitis. None of the
methicillin-sensitive isolates yielded staphylococci with het-
eroresistance to vancomycin subclones after screening by ei-
ther method. The antibiograms of the staphylococci with het-
eroresistance to vancomycin were similar to those of other
methicillin-resistant staphylococci isolated in this hospital in
that most were multiresistant to other antibiotics, including
erythromycin (100% resistance), clindamycin (100% resis-
tance), and gentamicin (66.7% resistance), but remained sus-
ceptible to fusidic acid (33.3% resistance).
The parent strains of the 18 staphylococcal isolates with
heteroresistance to vancomycin were all sensitive to vancomy-
cin (vancomycin MIC of ¶4 mg/mL) by conventional antibi-
otic susceptibility testing (table 2). Subclones selected out by
population screening or the disk-agar method showed 2- to
Table 2. Microbiological characteristics of staphylococci demonstrating vancomycin heteroresistance.
Case no. Strain identification
MIC of parent strain
at 24 h (mg/mL)
MIC of subclone after selection
at 24 h (mg/mL) Other antibiotic susceptibility
Without NaCl With 2% NaCl Without NaCl With 2% NaCl Cm Em FA Gm TMP-SMZ
70 Staphylococcus
aureus
1 1 8 8 R R S R S
231 S. aureus 1 2 8 16 R R S R S
500 S. aureus 2 2 8 8 R R S R S
17 Staphylococcus
epidermidis
2 8 8 32 R R S R R
37 S. epidermidis 2 2 16 32 R R R R R
148 S. epidermidis 2 4 8 16 R R S S S
412 S. epidermidis 2 2 8 8 R R R R R
425 S. epidermidis 2 2 8 16 R R S S R
431 S. epidermidis 2 2 8 8 R R R R R
52 Staphylococcus
capitis
1 1 16 64 R R S R S
106 S. capitis 2 4 16 16 R R S R S
159 S. capitis 2 2 8 16 R R R S S
446 Staphylococcus
haemolyticus
4 4 8 32 R R S R R
183 Staphylococcus
auricularis
2 4 16 16 R R R R S
427 Staphylococcus
simulans
2 4 16 64 R R S S S
428 Staphylococcus
warneri
2 2 8 16 R R S S S
56 Coagulase-negative
staphylococci
1 2 8 16 R R R S S
422 Coagulase-negative
staphylococci
2 4 8 8 R R S R R
NOTE. All isolates were methicillin-resistant. Cm 5 clindamycin; Em 5 erythromycin; FA 5 fusidic acid; Gm 5 gentamicin; R 5 resistant; S 5 susceptible;
TMP-SMZ 5 trimethoprim-sulfamethoxazole. Susceptibility to antibiotics other than vancomycin was determined by disk diffusion test and vancomycin MIC was
determined by the macrobroth dilution according to National Committee for Clinical Laboratory Standards methodology.
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16-fold increases in vancomycin MICs as determined by stan-
dard testing methods. The majority of subclones had vanco-
mycin MICs four- to eightfold higher than those of the parent
strains.
Increasing the time of incubation to 48 hours resulted in a
twofold rise in vancomycin MIC for a small number of parent
strains (four) and subclones (six) (data not shown). In contrast,
the addition of salt to the testing media showed a more prom-
inent effect on vancomycin MIC: Eight of the parent strains
and 11 of the subclones had two- to fourfold increases. The
effect of NaCl on vancomycin MIC is figuratively illustrated by
figure 1. Addition of 4% NaCl to Mueller-Hinton agar with 4
mg/mL vancomycin also markedly enhanced the phenomenon
of satellitism around the aztreonam disk (figure 2).
The clinical characteristics of the cases are summarized in
table 3. Eleven of the patients were admitted to the intensive
care unit during or at least 2 days before the date of bacteremia.
Cultures of blood from all case-patients yielded methicillin-
resistant staphylococci, and the episodes of bacteremia were
nosocomial in origin. Demographic and clinical data for the
cases and controls are compared in table 4. The ratio of males
to females was 13:5; the median age was 47.5 years. The
overall mortality rate of the case-patients was 44.4%, compared
with 10% in the control group. For seven of the cases, the
infective foci originated from an infected intravascular cathe-
ter. By use of univariate analysis, bacteremia due to staphylo-
cocci with heteroresistance to vancomycin was associated with
admission to the intensive care unit (P , .005), nosocomial
bacteremia (P , .005), administration of vancomycin (P ,
.001) and/or other b-lactam antibiotics (P , .05) within 1 week
of bacteremia, and methicillin-resistant staphylococcal bacte-
remia (P , .05). However, only the use of vancomycin (rela-
tive risk 5 9.45) and admission to the intensive care unit
(relative risk 5 3.47) were statistically significant (P , .05)
when these variables were analyzed by multivariate logistic
analysis.
Discussion
Glycopeptide resistance among gram-positive bacteria
has threatened the clinical usefulness of vancomycin and
teicoplanin. Two of the four reported clinical cases of in-
fection due to S. aureus with intermediate vancomycin re-
sistance were associated with failure of treatment with a
glycopeptide [1, 3]. A thorough understanding of the termi-
nology, laboratory detection, and clinical significance is
therefore essential to develop a rapid and sensitive method
for screening for S. aureus with intermediate vancomycin
resistance. The terminology of staphylococci with reduced
susceptibility to glycopeptides is still not standardized. With
the currently accepted NCCLS methodology and break
points [8], no true vancomycin resistance has been found
among clinical isolates [13]. Heteroresistance to vancomy-
cin was described among 5%–26% of methicillin-resistant
S. aureus isolates in Japanese hospitals [4].
The term “heteroresistance” may not be a satisfactory term
to encompass all staphylococci containing subpopulations with
elevated vancomycin MICs. First, the vancomycin MIC used to
define vancomycin-resistant S. aureus and S. aureus with het-
eroresistance to vancomycin were different in different studies.
Whereas the NCCLS break point for vancomycin resistance is
Ä32 mg/mL, a vancomycin MIC of Ä8 mg/mL was used in a
subsequent study [4]. Indeed, in the latter report of 35 S. aureus
with heteroresistance to vancomycin, the highest vancomycin
MIC of the “resistant” subclones was 7 mg/mL, which is,
strictly speaking, intermediate vancomycin heteroresistance. In
our study, the vancomycin MICs of the subclones were 8–16
Figure 2. Satellitism of Staphylococcus aureus (case no. 70)
around b-lactam antibiotic disks on Mueller-Hinton agar plates with
4 mg/mL vancomycin. A, Agar plate without addition of NaCl; B, agar
plate with the addition of 4% NaCl. 1 5 aztreonam; 2 5 ceftibuten;
3 5 oxacillin; 4 5 cefoxitin.
Figure 1. Vancomycin MIC of Staphylococcus capitis (case no.
159) determined by Etest. A, Tested on Mueller-Hinton agar; B, tested
on Mueller-Hinton agar with the addition of 4% NaCl.
763Vancomycin-Heteroresistant StaphylococciCID 1999;29 (October)
mg/mL as determined by use of standard methodology (24
hours of incubation in the absence of added salt; table 2).
Higher vancomycin MICs in the range of resistance can be
observed only after 48 hours of incubation and/or addition of
salt to the testing media.
Second, the conventional concept of methicillin “heterore-
Table 3. Clinical characteristics of patients with bacteremia due to vancomycin-heteroresistant staphylococci.
Case no. Sex
Age
(years) Underlying disease Infective focus
Antimicrobial agent(s) administered
before or during blood culture* Outcome
70 M 78 Chronic renal failure, receiving
chronic ambulatory
peritoneal dialysis
Sepsis and acute pyogenic
arthritis of the right
shoulder
None Died despite Vm and Rif
231 F 53 Mycosis fungoides, undergoing
chemotherapy
Neutropenic sepsis Vm, Imi, Amik, Flu Died despite continuing
therapy
500 M 77 Carcinoma of stomach; given
one course of regional
chemotherapy before
admission
Central venous catheter Vm Afebrile after
vancomycin and oral
fusidic acid
17 M 65 Subarachnoid hemorrhage,
hydrocephalus, coma;
ventriculoperitoneal shunt in
situ
Central venous catheter Ctri Recovered after removal
of catheter
37 M 34 Carcinoma of colon,
postcolectomy, short gut
syndrome after resection for
radiation enteritis
Central venous catheter None Recovered after removal
of Broviac catheter
148 F 0.5 Prematurity, necrotizing
enterocolitis, anastomotic
leakage
Sepsis, peritonitis Czid, Vm Died despite addition of
Mtz
412 F 44 Acute traumatic subdural
hematoma, fractured cervical
spine, quadriplegia
Central venous catheter Pip/Taz, Gm Recovered after removal
of central venous
catheter
425 F 59 Traumatic fracture of the skull
and coma after craniectomy
Central venous catheter Vm, Ctri, Flu Recovered after removal
of central venous
catheter and addition
of fusidic acid
431 M 0.45 Prematurity, short gut
syndrome after resection for
necrotizing enterocolitis
Sepsis Czid, Clox, Mtz Died despite switching
from Clox to Vm
52 M 0.2 Gut resection for malrotation
and volvulus
Central venous catheter Czid, Mtz Recovered after removal
of Broviac and
addition of Vm
106 M 64 Subarachnoid hemorrhage,
hydrocephalus, coma;
ventriculoperitoneal shunt in
situ
Central venous catheter Ctri Recovered after removal
of central venous
catheter
159 M 14 d Prematurity Sepsis Vm Recovered
446 M 17 Acute myeloid leukemia,
undergoing chemotherapy
Neutropenic sepsis Imi, Vm Afebrile after WBC
count returned to
normal
183 M 23 Lymphoma, undergoing
chemotherapy
Neutropenic sepsis Imi, Vm Died
427 M 62 Acute myeloid leukemia Neutropenic sepsis Cpfx Died despite Vm, Czid,
and Mtz
428 M 0.5 Meconium ileus and
peritonitis, Hirschsprung’s
disease
Sepsis Czid, Vm, Mtz Died despite addition of
Net
56 M 76 Hodgkin’s lymphoma,
undergoing chemotherapy
Neutropenic sepsis Czid Died despite Vm and
Cpfx
422 F 51 Carcinoma of the lung,
undergoing chemotherapy
Neutropenic sepsis Meropenem Died despite addition of
Vm
NOTE. Amik 5 amikacin; Clox 5 cloxacillin; Cpfx 5 ciprofloxacin; Ctri 5 ceftriaxone; Czid 5 ceftazidime; F 5 female; Flu 5 fluconazole; Gm 5
gentamicin; Imi 5 imipenem; M 5 male; Mtz 5 metronidazole; Net 5 netilmicin; Pip 5 piperacillin; Rif 5 rifampin; Taz 5 tazobactam; Vm 5 vancomycin.
* Route of administration of all antibiotics is iv unless otherwise stated.
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sistance” in S. aureus refers to the occurrence of phenotypic
resistance at a low frequency (;1 in 106) [14]; subculturing
these resistant subpopulations on antibiotic-free media gener-
ally does not result in the appearance of homogenous resis-
tance. This is in contrast with our experience in that the
subclones with elevated vancomycin MICs are often phenotyp-
ically homogenous. A more exact description should therefore
be “staphylococci with subpopulations showing reduced sus-
ceptibility to vancomycin.” A better and more precise defini-
tion awaits a consensus on these issues and more information
on the genetic basis of these staphylococci.
Vancomycin “heteroresistance” nevertheless resembles
methicillin heteroresistance in other respects. Staphylococcal
resistance to methicillin is better demonstrated under condi-
tions such as neutral to slightly alkaline media, lower incuba-
tion temperature, or the presence of an increased concentration
of salt [15]. The role of these conditions in the induction of
vancomycin resistance is less clear. Among S. haemolyticus,
vancomycin-resistant subclones demonstrated a double-zone
phenomenon around a 10-mg imipenem disk, presumably be-
cause of induction by b-lactam antibiotics [5]. Addition of 2%
NaCl to the medium also enhanced the growth of these sub-
clones in the presence of high concentrations of vancomycin.
This is, however, the first time that these properties have been
used for the detection of vancomycin resistance in S. aureus.
The mechanism by which these two factors enhance the ex-
pression of heteroresistance to vancomycin is not known. How-
ever, vancomycin-resistant S. aureus mutants thus far selected
have been shown to have markedly thickened cell walls and
were able to bind vancomycin present in the media [16]. It has
also been demonstrated that glycopeptide resistance in S. au-
reus is associated with increased production of penicillin-
binding proteins, most notably penicillin-binding protein 2
[17]. The increased production of peptidoglycan cell wall ma-
terial in turn binds a large amount of vancomycin, resulting in
blockage of cell autolysis, depletion of vancomycin in the
medium, and steric hindrance so that free vancomycin in the
environment is not able to penetrate the cell wall to bind to the
D-alanyl-D-alanine termini of new muropeptides [16]. As the
phenotypic expression of methicillin resistance in staphylo-
cocci can also be induced by the presence of a higher salt
concentration [18], this might provide clues for further study of
the association between higher salinity and the expression of
vancomycin resistance.
The disk-agar screening method was based on the above ob-
servations with vancomycin-salt agar together with the demon-
stration of satellitism around a 30-mg aztreonam disk. The agar
screening method is at present the only available screening
method for the detection of S. aureus with intermediate vanco-
mycin resistance but not staphylococci with heteroresistance to
vancomycin [12]. The disk-agar method therefore has the advan-
tage of demonstrating both the presence of potential intermedi-
ately vancomycin-resistant staphylococci and staphylococci with
heteroresistance to vancomycin on the same plate. Aztreonam was
preferred over other b-lactam antibiotics because it has no inhib-
itory effect on gram-positive bacteria. A preliminary study of the
disk-agar screen method was done with different b-lactams in-
cluding penicillins, oxacillin, cephalosporins, and carbapenems
(data not shown). Although satellitism can sometimes be seen
around other b-lactam disks, the results were less consistent than
they were for aztreonam, and some strains had a large zone of
inhibition around the disk (e.g., around the cefoxitin disk in figure
2). Besides being a useful test for screening for staphylococci with
heteroresistance to vancomycin and those with intermediate resis-
tance to vancomycin, the results also conclusively demonstrated
the inducibility of vancomycin resistance by NaCl and b-lactams.
The effect of additional NaCl on the induction of vancomy-
cin heteroresistance is also remarkable. The vancomycin MIC
was increased two- to fourfold in the presence of NaCl (table
2, figure 1). This phenomenon is echoed by the fact that
Table 4. Risk factors for bacteremia due to vancomycin-
heteroresistant staphylococci.
Cases
(n 5 18)
Controls
(n 5 30) P*
Sex ratio (M:F) 13:5 19:11 NS
Age
Median (y) 47.5 57.5 NS
Range 14 d–78 y 16 d–78 y
Type of ward
Adult and neonatal ICU 11 6 ,.005†
Hematology and oncology 3 3 NS
General medical/surgical 4 21 ,.001
Underlying diseases‡
Fatal — — NS
Ultimately fatal 9 12 NS
Nonfatal 9 18 NS
Interval between day of
admission to bacteremia
¶2 d — 11 ,.005
Median (d) 14.5 9.0
Range (d) 3–160 0–64
Vancomycin (iv) given
within 1 w of
bacteremia 8 (44.4%)§ 1 (3.0%) ,.001†
b-lactam (iv) given within
1 w of bacteremia 13 (72.2%)§ 12 (40.0%) ,.05
Bacteremia due to
methicillin-resistant
staphylococci 18 (100%) 19 (63.3%) ,.05
Bacteremia due to
Staphylococcus aureus 3 (16.7%) 21 (70.0%) ,.001
Deaths 8 (44.4%) 3 (10.0%)
NOTE. Data are no., no. (%), or specified unit. F 5 female; ICU 5
intensive care unit; M 5 male.
* By univariate analysis. NS 5 not significant.
‡ The nature of underlying illness was classified according to [12].
§ Six patients concomitantly received vancomycin and a b-lactam antibiotic.
† Also significant by multivariate logistic analysis (P , .05). Relative risk
associated with admission to ICU 5 9.45; relative risk associated with use of
vancomycin 5 3.47.
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satellitism is also much more pronounced in the presence of 4%
NaCl (figure 2). Hence, although additional NaCl is not re-
quired for determination of the vancomycin MIC by broth
dilution, a higher salt concentration could be essential for the
demonstration of heteroresistance, at least in the screening step.
Inducible heteroresistance to vancomycin (table 2) is seen
primarily among methicillin-resistant staphylococci (100% in
our study), with 83.3% of these 18 strains being CNS. The
significance of this finding is uncertain, but it has been well
known that some clinical isolates of S. haemolyticus and S. epi-
dermidis are resistant to vancomycin [19]. We speculate that
the emergence of vancomycin resistance might first appear
among commensal CNS and perhaps as staphylococci with
heteroresistance to vancomycin, which may then spread to
S. aureus, a hypothesis that is analogous to the postulation that
the mecA gene accounting for methicillin resistance might have
originated from CNS [14, 20]. Assuming that the emergence of
vancomycin resistance, like methicillin resistance, is related to
antibiotic selection pressure, vancomycin heteroresistance
among CNS may herald its appearance in S. aureus.
The clinical significance of intermediate vancomycin resis-
tance among S. aureus is currently limited to four case reports
with at least two treatment failures when glycopeptides were
used. Even less is known about its significance in CNS. This is
the first case-control study that attempts to answer these ques-
tions.
The isolation of staphylococci with heteroresistance to
vancomycin was largely from patients in the intensive care
unit. This is not unexpected, since the only significant
independent risk factors for the isolation of staphylococci
with heteroresistance to vancomycin as determined by mul-
tivariate analysis were the use of vancomycin within 1 week
of bacteremia and admission to the intensive care unit (table
4), and the consumption of vancomycin in our hospital is
highest in these wards (data not shown). Although not
significant as an independent risk factor, use of b-lactam
antibiotics may also be associated with a higher risk of
bacteremia due to staphylococci with heteroresistance to
vancomycin. Prior use of b-lactams may serve to induce the
expression of vancomycin resistance; the sequential use of
vancomycin could then exert its effects through selection of
vancomycin-resistant subclones in vivo.
It is notable that six of the case-patients received vancomy-
cin and b-lactam antibiotics concomitantly at the time of bac-
teremia, whereas none in the control group had received this
combination. The emergence of staphylococci with heterore-
sistance to vancomycin, which are invariably methicillin-
resistant, could be related to the common practice of empirical
b-lactam therapy for sick febrile patients; a lack of response is
often followed by addition of a glycopeptide because of the
high incidence of superinfection with methicillin-resistant
S. aureus in our hospital [21]. A prospective study should be
done to ascertain the true significance of bacteremia due to
vancomycin-heteroresistant staphylococci.
Staphylococci with heteroresistance to vancomycin are
likely to be nosocomial pathogens, as their occurrence is asso-
ciated with nosocomial staphylococcal bacteremia, and all of
the isolates in this study were methicillin-resistant. The con-
trols were more likely to have bacteremia due to S. aureus (P ,
.001), which is related to the fact that the bacteremic episodes
in the controls more frequently represented community-
acquired infections and many were due to methicillin-sensitive
S. aureus. In contrast, 83.3% of the staphylococci with hetero-
resistance to vancomycin were CNS, which could be related to
intravascular catheter–associated sepsis in hospitalized pa-
tients. CNS are the most common pathogens causing nosoco-
mial catheter-related sepsis [22]; seven of the cases had the
source of bacteremia traced to infected catheters.
The overall mortality from bacteremia due to staphylococci
with heteroresistance to vancomycin is higher than that in
patients with fully vancomycin-sensitive isolates (44.4% vs.
10%). The difference in mortality is unlikely to be due to the
differences in the nature of underlying diseases (table 4) but is
probably related to the suboptimal response to the antibiotics
used. Nevertheless, direct comparison of the overall mortality
rate is unsatisfactory, since the total number of patients is
small, and the number of deaths directly attributable to the
episode of staphylococcal bacteremia is difficult to ascertain in
a retrospective study.
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